Evaluation of a large-scale aptamer proteomics platform among patients with kidney failure on dialysis.

Yue RenPeifeng RuanMark SegalMirela DobreJeffrey R SchellingUpasana BanerjeeTariq ShafiPeter GanzRuth F Dubinnull null

Published in: PloS one (2023)

SomaScan had excellent technical variability and low within-subject short-term variability. ANML formatting could facilitate comparison of biomarker results with other studies that utilize this format. We expect SomaScan to provide novel and reproducible information in patients with kidney failure on dialysis.

Keyphrases

chronic kidney disease
end stage renal disease
peritoneal dialysis
label free
mass spectrometry
gold nanoparticles
high throughput
finite element
single cell
quantum dots